Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Francesca's (FRAN) upgraded to Buy from Neutral at B. Riley FBR with analyst Susan Anderson saying she has increased confidence in the company's turnaround following meetings with management. 2. Chevron (CVX) upgraded to Outperform from Market Perform at Raymond James with analyst Pavel Molchanov saying Chevron offers relatively more leverage than most peers to higher oil prices, which should reach cyclical highs over the next 6 to 12 months, while low WTI exposure maximizes earnings and free cash flow generation. 3. Trovagene (TROV) upgraded to Buy from Hold at Maxim with analyst Jason McCarthy citing the positive news from the company's lead drug candidate PCM-075 as well as its completion of a capital raise. 4. RBS (RBS) upgraded to Buy from Hold at Investec. 5. Teva (TEVA) upgraded to Market Perform from Underperform at Wells Fargo with analyst David Maris citing a "positive meeting" with Teva's CEO Kundefinedre Schultz and CFO Mike McClellan in Israel. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage,
click here.